- Home
- RLAY vs NEO Comparison
RLAY vs NEO Comparison
Compare RLAY & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLAY | NEO |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2020 | 1999 |
Fundamental Metrics
Financial Performance| Metric | RLAY | NEO |
|---|---|---|
| Price | $8.66 | $12.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $16.00 | $11.38 |
| AVG Volume (30 Days) | ★ 2.3M | 1.7M |
| Earning Date | 11-06-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $8,355,000.00 | ★ $709,162,000.00 |
| Revenue This Year | $20.47 | $10.90 |
| Revenue Next Year | N/A | $9.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.10 |
| 52 Week Low | $1.78 | $4.72 |
| 52 Week High | $9.04 | $19.12 |
Technical Indicators
Market Signals| Indicator | RLAY | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 66.27 | 66.01 |
| Support Level | $7.95 | $11.46 |
| Resistance Level | $9.04 | $12.19 |
| Average True Range (ATR) | 0.50 | 0.40 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 75.93 | 85.29 |
Price Performance
Historical ComparisonAbout RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.